In 2016, the investments into the fixed capital of pharmaceutical industry of the Republic of Kazakhstan reached 11.5 billion tenge, which is 6% more than in 2015.
Higher investment volume can be explained by the fact that more than 10 pharmaceutical enterprises, including those with foreign capital, have been put into operation over the past five years. Kazakhstani pharmaceutical enterprises are implementing the planned modernization of their existing capacities and mastering new competencies in the area of manufacturing.
Zhenis Kasymbek, the Minister for Investments and Development of Kazakhstan, spoke about the implementation of the project to build a pharmaceutical plant by Hikma, a transnational company, within the Alatau industrial zone in Almaty. The plant is expected to start up the manufacturing of pharmaceuticals for cardiovascular diseases and diseases of central nervous system. The production capacity will reach 300 million tablets and 90 million capsules per year, and will lead to creation of 120 jobs. The project cost is $40 million.
In addition, a project on manufacturing the medicinal products worth 7 billion tenge is being implemented in Atyrau together with Indian investors.
Another project on manufacturing of solutions for infusion worth 2 billion tenge is being implemented in Aktau.